Literature DB >> 17947785

How can we regulate medicines better?

Silvio Garattini1, Vittorio Bertele'.   

Abstract

Mesh：

Year:  2007        PMID： 17947785      PMCID： PMC2034743          DOI： 10.1136/bmj.39281.615706.94

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  Adjusting Europe's drug regulation to public health needs.

Authors:  S Garattini; V Bertele
Journal:  Lancet       Date:  2001-07-07       Impact factor: 79.321

2.  A model for the future conduct of pharmacovigilance.

Authors:  Patrick C Waller; Stephen J W Evans
Journal:  Pharmacoepidemiol Drug Saf       Date:  2003 Jan-Feb       Impact factor: 2.890

3.  How can research ethics committees protect patients better?

Authors:  Silvio Garattini; Vittorio Bertele; Luca Li Bassi
Journal:  BMJ       Date:  2003-05-31

4.  In the dark: drug companies should be forced to publish all the results of clinical trials.

Authors:  Iain Chalmers
Journal:  New Sci       Date:  2004 Mar 6-12       Impact factor: 0.319

5.  Open access to industry's clinically relevant data.

Authors:  Andrew Herxheimer
Journal:  BMJ       Date:  2004-07-10

6.  Postmarketing surveillance--lack of vigilance, lack of trust.

Authors:  Phil B Fontanarosa; Drummond Rennie; Catherine D DeAngelis
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

7.  Quality control in the regulation of pharmaceuticals.

Authors:  Alan Maynard
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.

Authors:  David J Graham
Journal:  JAMA       Date:  2006-09-12       Impact factor: 56.272

9.  Statistical power, sample size, and their reporting in randomized controlled trials.

Authors:  D Moher; C S Dulberg; G A Wells
Journal:  JAMA       Date:  1994-07-13       Impact factor: 56.272

10.  Content and quality of 2000 controlled trials in schizophrenia over 50 years.

Authors:  B Thornley; C Adams
Journal:  BMJ       Date:  1998-10-31
View more
  15 in total

1.  Risk Management Plans: are they a tool for improving drug safety?

Authors:  Serena Frau; Maria Font Pous; Maria Rosa Luppino; Anita Conforti
Journal:  Eur J Clin Pharmacol       Date:  2010-06-25       Impact factor: 2.953

2.  The Italian Horizon Scanning Project.

Authors:  Roberta Joppi; Luca Demattè; Anna Michela Menti; Daniela Pase; Chiara Poggiani; Luigi Mezzalira
Journal:  Eur J Clin Pharmacol       Date:  2009-06-03       Impact factor: 2.953

3.  Enhancing the rational use of new medicines across European health care systems.

Authors:  Silvio Garattini; Vittorio Bertele'; Brian Godman; Alan Haycox; Björn Wettermark; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2008-12       Impact factor: 2.953

Review 4.  Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

Authors:  Björn Wettermark; Brian Godman; Karolina Andersson; Lars L Gustafsson; Alan Haycox; Vittorio Bertele
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 5.  Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Eric Abadie; David Barnett; Franz König; Steven Pearson
Journal:  Nat Rev Drug Discov       Date:  2010-02-26       Impact factor: 84.694

6.  HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2020-02

Review 7.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

8.  Does the development of new medicinal products in the European Union address global and regional health concerns?

Authors:  Ferrán Catalá-López; Anna García-Altés; Elena Alvarez-Martín; Ricard Gènova-Maleras; Consuelo Morant-Ginestar
Journal:  Popul Health Metr       Date:  2010-12-20

9.  Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network (ECRIN) countries.

Authors:  Christian Gluud; Christine Kubiak; Kate Whitfield; Jane Byrne; Karl-Heinz Huemer; Steffen Thirstrup; Christian Libersa; Béatrice Barraud; Xina Grählert; Gabriele Dreier; Sebastian Geismann; Wolfgang Kuchinke; Zsuza Temesvari; Gyorgy Blasko; Gabriella Kardos; Timothy O'Brien; Margaret Cooney; Siobhan Gaynor; Arrigo Schieppati; Fernando de Andres; Nuria Sanz; German Kreis; Charlotte Asker-Hagelberg; Hanna Johansson; Sue Bourne; Adeeba Asghar; Jean-Marc Husson; Jacques Demotes-Mainard
Journal:  Trials       Date:  2012-03-27       Impact factor: 2.279

10.  A New Vaccine for Tuberculosis: The Challenges of Development and Deployment.

Authors:  Helen A Fletcher; Tony Hawkridge; Helen McShane
Journal:  J Bioeth Inq       Date:  2009-05-05       Impact factor: 1.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.